Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have earned a consensus recommendation of “Moderate Buy” from the ten analysts that are currently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $6.5714.

Several equities research analysts recently commented on the stock. Mizuho dropped their price objective on shares of Neumora Therapeutics from $6.00 to $4.00 and set an “outperform” rating on the stock in a research note on Thursday, June 18th. HC Wainwright reiterated a “buy” rating on shares of Neumora Therapeutics in a report on Tuesday, July 28th. Wall Street Zen raised Neumora Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings downgraded Neumora Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 14th. Finally, Royal Bank Of Canada reduced their price objective on Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating for the company in a research report on Monday, July 13th.

Neumora Therapeutics Price Performance

Shares of NMRA stock opened at $1.52 on Tuesday. The business’s fifty day moving average is $1.61 and its 200 day moving average is $2.10. The company has a quick ratio of 4.50, a current ratio of 4.50 and a debt-to-equity ratio of 1.19. The stock has a market cap of $286.55 million, a price-to-earnings ratio of -1.24 and a beta of 2.75. Neumora Therapeutics has a twelve month low of $0.83 and a twelve month high of $3.65.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.01. Research analysts expect that Neumora Therapeutics will post -0.85 EPS for the current fiscal year.

Insider Buying and Selling at Neumora Therapeutics

In other news, insider Daljit Singh Aurora sold 91,690 shares of Neumora Therapeutics stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1.50, for a total value of $137,535.00. Following the completion of the transaction, the insider owned 48,750 shares of the company’s stock, valued at $73,125. The trade was a 65.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 453,833 shares of company stock worth $701,219 in the last ninety days. 26.94% of the stock is owned by company insiders.

Institutional Trading of Neumora Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of NMRA. HBK Sorce Advisory LLC purchased a new position in Neumora Therapeutics in the second quarter worth about $26,000. Hsbc Holdings PLC bought a new stake in shares of Neumora Therapeutics during the fourth quarter valued at approximately $27,000. Virtu Financial LLC purchased a new position in Neumora Therapeutics in the 3rd quarter worth approximately $31,000. Fred Alger Management LLC bought a new position in Neumora Therapeutics in the 4th quarter valued at approximately $40,000. Finally, Canada Pension Plan Investment Board purchased a new stake in Neumora Therapeutics during the 2nd quarter valued at $41,000. 47.65% of the stock is currently owned by institutional investors.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.